MAPS Statement on Bipartisan Congressional Letter to FDA
Washington DC — Reps. Jack Bergman (R-MI) and Lou Correa (D-CA), co-chairs of the Congressional Psychedelics Advancing Therapies Caucus, led a bipartisan group of 30 members of Congress in a letter to Food and Drug Administration (FDA) Commissioner Martin A. Makary, urging the agency to advance evaluation of psychedelic-assisted therapies. The letter asks FDA to… Continue reading MAPS Statement on Bipartisan Congressional Letter to FDA
External link. We are not responsible for the content.
Read more ↗More From MAPS
Protected: 2026 Second Quarter — Policy & Advocacy Wrap Up
There is no excerpt because this is a protected post.
Protected: MAPS Publishes Ibogaine Investigator’s Brochure as a Free, Open-Access Resource
There is no excerpt because this is a protected post.
Psychedelic Science 2027 Speaker Submission Invites the Field to Bridge Promise and Practice
June, 25, 2026 — The Multidisciplinary Association for Psychedelic Studies (MAPS) announced the opening of speaker su...
Latest News
The Rush for Iboga Looks Different from Gabon
Gabonese civil servant and environmental lawyer Georges Gassita on what the ibogaine rush looks like from inside Gabo...
The Psychedelic Sector Has Grown Up. Wall Street Just Hasn’t Fully Realized It Yet
The sector experienced an early wave of enthusiasm fueled by bold promises, lofty valuations, and the belief that psy...
Do people hear voices when they take ayahuasca? 5 Questions with social anthropologist David Dupuis
Dupuis discusses how auditory hallucinations during psychedelic trips have been overlooked.
One of Psychedelia’s Most Notorious Gurus Is Officially Put on Blast
PLUS, stories about datura, the Huni Kuin, and Oregon's drug policy programs. [...] Read More... The post One of Psyc...
LSD Just Joined The Establishment
This Week’s Sunday Insider: The most anti-establishment Psychedelic in history is becoming part of the establishment.
Big changes ahead for Oregon’s psilocybin agency, New bill seeks to turn Trump’s psychedelics executive order into permanent law
Plus: Compass Pathways announces new Phase 3 results, and Lawsuit against LSD company Definium is dismissed